Lexicon Pharmaceuticals Inc (LXRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.24-0.88%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LXRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 75.1% |
| Our one-year growth estimate | diamond | -42.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 117.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
LXRX — earnings in line
Dated 2026-08-06
Results of Operation and Financial Condition On August 6, 2026, we issu ed a press release to report our financial results for the quarter ended June 30, 2026. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section…
Why it matters: Securing funding is crucial for Lexicon's operations and growth plans. It impacts their ability to manage losses and invest in growth.
Supportive ifThey announced new loans or funding over $50 million.
Worry ifNo new funding announcements or delays in securing loans.
Why it matters: If healthcare sector revenue growth speeds up, it may benefit Lexicon. A strong sector can lift all companies.
Supportive ifHealthcare sector revenue growth exceeds 10% year over year.
Worry ifHealthcare sector revenue growth remains below 10% year over year.
Why it matters: The next earnings report will show how much revenue grew and losses occurred.
Watch forEarnings report shows revenue growth above $21.1 million.
Also watch forEarnings report shows revenue growth below $21.1 million.
Why it matters: Finishing enrollment in the SONATA-HCM trial is key for getting the drug approved.
Supportive ifEnrollment in the SONATA-HCM trial is completed by mid-2026.
Worry ifEnrollment is not completed by mid-2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$220 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $678 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,409 loss on $10,000 · 34.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Topline data will show how well sotagliflozin works for HCM. This could impact future sales and growth.
Supportive ifThe SONATA-HCM study shows major improvements in how patients feel.
Worry ifThe results show no big improvements in patient symptoms.
Why it matters: If ZYNQUISTA is approved, it will give more treatment options for type 1 diabetes.
Supportive ifZYNQUISTA's NDA resubmission is done and meets FDA rules.
Worry ifNDA resubmission for ZYNQUISTA is delayed or fails to meet FDA requirements.
Why it matters: Completing this study could bring big payments and future money from LX9851.
Supportive ifThe Phase 1 study of LX9851 is done and meets safety and effectiveness goals.
Worry ifPhase 1 study of LX9851 is delayed or does not meet safety and efficacy endpoints.